Background Pre‐eclampsia is associated with deficient intravascular production of
prostacyclin, a vasodilator, and excessive production of thromboxane, a vasoconstrictor and …

Background Pre‐eclampsia is associated with deficient intravascular production of
prostacyclin, a vasodilator, and excessive production of thromboxane, a platelet‐derived …

Background Pre-eclampsia is a major cause of mortality and morbidity during pregnancy
and childbirth. Antiplatelet agents, especially low-dose aspirin, might prevent or delay pre …

Objective: To assess the effectiveness and safety of antiplatelet drugs for prevention of pre-
eclampsia and its consequences. Design: Systematic review. Data sources: Register of trials …

Background The optimum time for commencing antiplatelet therapy for the prevention of
preeclampsia and its complications is unclear. Aggregate data meta-analyses suggest that …

Preeclampsia is an obstetric disorder that affects 3–8% of pregnant women and remains a
leading cause of short-and long-term neonatal and maternal morbidity and mortality …

Objective Data Metaanalyses of randomized controlled trials have reported contradictory
results about the effect of aspirin in the prevention of preeclampsia, both in terms of the …

OBJECTIVE: Spontaneous preterm birth is an important cause of neonatal mortality and
morbidity. An increasing body of evidence suggests that uteroplacental ischemia plays an …

The road to low-dose aspirin therapy for the prevention of preeclampsia began in the 1980s
with the discovery that there was increased thromboxane and decreased prostacyclin …

OBJECTIVE: To examine the effectiveness of aspirin in preventing perinatal death and
preeclampsia in women with predisposing historical risk factors, such as previous history of …